GUERBET Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GUERBET, and what generic alternatives to GUERBET drugs are available?
GUERBET has five approved drugs.
There are three US patents protecting GUERBET drugs.
There are seventy-three patent family members on GUERBET drugs in twenty-six countries and one supplementary protection certificate in one country.
Summary for GUERBET
International Patents: | 73 |
US Patents: | 3 |
Tradenames: | 6 |
Ingredients: | 5 |
NDAs: | 5 |
Drug Master File Entries: | 1 |
Drugs and US Patents for GUERBET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Guerbet | DOTAREM | gadoterate meglumine | SOLUTION;INTRAVENOUS | 204781-002 | Mar 20, 2013 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-004 | Sep 21, 2022 | RX | Yes | Yes | 11,590,246 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-007 | Sep 21, 2022 | RX | Yes | Yes | 10,973,934 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Guerbet | OXILAN-300 | ioxilan | INJECTABLE;INJECTION | 020316-001 | Dec 21, 1995 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-005 | Sep 21, 2022 | RX | Yes | Yes | 10,973,934 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Guerbet | DOTAREM | gadoterate meglumine | SOLUTION;INTRAVENOUS | 204781-001 | Mar 20, 2013 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-005 | Sep 21, 2022 | RX | Yes | Yes | 11,590,246 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GUERBET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | 4,014,986 | ⤷ Sign Up |
Guerbet | OXILAN-350 | ioxilan | INJECTABLE;INJECTION | 020316-002 | Dec 21, 1995 | 4,954,348 | ⤷ Sign Up |
Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | 4,094,966 | ⤷ Sign Up |
Guerbet | OXILAN-300 | ioxilan | INJECTABLE;INJECTION | 020316-001 | Dec 21, 1995 | 4,954,348 | ⤷ Sign Up |
Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | 4,065,554 | ⤷ Sign Up |
Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | 4,065,553 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for GUERBET Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 284884 | ⤷ Sign Up |
China | 112533921 | ⤷ Sign Up |
South Korea | 101440761 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2020030618 | ⤷ Sign Up |
Japan | 7321230 | ⤷ Sign Up |
France | 2891830 | ⤷ Sign Up |
China | 101305006 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for GUERBET Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1931673 | 301259 | Netherlands | ⤷ Sign Up | PRODUCT NAME: GADOPICLENOL; REGISTRATION NO/DATE: EU/1/23/1772 20231208 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.